A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression

Trial Profile

A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
    • 21 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top